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Figure 1 – Mortality.
Nesiritide Placebo        Risk difference Risk difference
Study or subgroup Events Total Events Total Weight       M-H, Fixed, 95% CI M-H, Fixed, 95% CI
O’Connor6 126 3564 141 3577 93.3% -0.00 [-0.01, 0.00]
Miller et al.7 1 53 4 48 1.3% -0.06 [-0.15, 0.02]
Peacock et al.8 5 127 1 123 3.3% -0.03 [-0.01, 0.07]
Mills10 (0,015 μg) 0 22 3 29 0.7% -0.10 [-0.23, 0.03]
Mills10 (0,03 μg) 1 26 3 29 0.7% -0.06 [-0.20, 0.07]
Mills10 (0,06 μg) 1 26 3 29 0.7% -0.06 [-0.20, 0.07]
Total (95% CI) 3818 3835 100.0% -0.01 [-0.01, -0.00]
Total events 134 155
Heterogeneity: Chi2 = 9.29; df = 5 (p < 0.010); I 2 = 46%
Test for overall effect: Z = 1.20 (p = 0.23) Favours nesiritide
-0.2 -0.1 0.1 0.20
Favours placebo
*Meta-analysis of selected studies. Overall result expressed in the difference of absolute risk, with no statistically signiﬁcant beneﬁt.
INTRODUCTION 
Heart failure (HF) is characterized by insufficient cardiac 
output to supply adequate perfusion to the peripheral de-
mands. When decompensated, it can cause various sys-
temic effects, depending on the type of presentation. The 
patient may have only a low cardiac output, or may have 
a large pulmonary vascular congestion, causing acute pul-
monary edema and clinically important dyspnea.
Nesiritide is a recombinant form of brain natriuretic 
peptide (BNP), secreted when the walls of the heart’s ven-
tricles are dilated, and its use was approved in 2001 by the 
FDA for the treatment of decompensated HF. It has va-
sodilatory properties, causing reduced pre- and afterload, 
decreased pulmonary capillary pressure, and increased 
cardiac output without inotropic effects1,2 and without 
causing arrhythmias3.
The objective of this review is to evaluate whether the 
use of nesiritide brings benefit or harm to patients present-
ing to the emergency department with dyspnea for HF de-
compensation.
METHOD
A systematic review was conducted in the MEDLINE da-
tabase to find the best evidence available with the follow-
ing strategy: [(Natriuretic Peptide, Brain OR Nesiritide) 
AND (Dyspnea OR Heart failure)]. The Therapy/Narrow 
filter was used through the Clinical Queries interface.
Each retrieved study was evaluated by title and sum-
mary. The selected studies met the following inclusion cri-
teria: randomized clinical trial; use of nesiritide compared 
with placebo (both combined with standard therapy) in 
patients presenting to the emergency department with de-
compensated HF/dyspnea; and written in English, Span-
ish, or Portuguese. Only studies with a Jadad et al.4 score 
greater than or equal to three were included in the final 
selection and data analysis.
All variables were analyzed through the CATmaker 
software, using the difference in absolute risk (AR), with 
95% confidence interval (95% CI), and the number needed 
to treat (NNT) or number needed to harm (NNH). Meta-
analysis was performed using the Review Manager 5.1.2 
software.
Figure 2 – Heterogeneity test.
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*Funnel Plot – Studies in the funnel area are considered homogeneous.
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Figure 3 – Readmission.
*Meta-analysis of selected studies. Overall result expressed in the difference of absolute risk, with no statistically signiﬁcant beneﬁt.
Nesiritide Placebo        Risk difference Risk difference
Study or subgroup Events Total Events Total Weight       M-H, Fixed, 95% CI M-H, Fixed, 95% CI
O’Connor6 204 3564 208 3577 95.3% -0.00 [-0.01, 0.01]
Miller et al.7 22 53 19 48 1.3% -0.02 [-0.17, 0.21]
Peacock et al.8 6 127 15 123 3.3% -0.07 [-0.14, -0.01]
Total (95% CI) 3744 3748 100.0% -0.00 [-0.01, 0.01]
Total events 232 242
Heterogeneity: Chi2 = 4.40; df = 2 (p = 0.11); I 2 = 54%
Test for overall efect: Z = 0.56 (p = 0.58) Favours nesiritide
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Favours placebo
0.2
0 SE (RD)
RD
Figure 4 – Heterogeneity test.
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*Funnel Plot – Studies in the funnel area are considered homogeneous.
RESULTS
The literature review was completed in August 2011. We 
retrieved 411 articles, but only seven5-11 met the inclusion 
criteria. After analysis of the selected articles, two were ex-
cluded from the final selection; one5 for not having a place-
bo group for comparison, and the other11 for not providing 
absolute data on the outcomes,  preventing the calculation 
of risk difference.
In the study by Colucci et al.9, two doses of nesiritide 
were tested (0.015 and 0.030 g/kg/min) and compared to 
placebo. Mills et al.10 tested three doses (0.015, 0.03, and 
0.06 g/kg/min) compared to placebo.
MORTALITY
Four studies6-8,10 presented data on mortality (Figures 1 
and 2). There was no statistically significant difference 
in risk for both the effect of individual studies and the 
overall effect.
READMISSION
Of the three studies6-8 evaluating the number of readmis-
sions, only one study8 showed a significant benefit of ne-
siritide. However, there was no significant difference in the 
overall effect (Figures 3 and 4).
CONCLUSION
Analysis of best available evidence shows that the use of 
nesiritide is safe because it did not cause significant differ-
ences in mortality and readmission rates.
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